Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization

Molecular Vision

Volumn 18, Issue , 2012, Pages 574-580

  Miao, Heng ^a,b   Tao, Yong ^a,b   Li, Xiao Xin ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MYOPIA; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; RETINA MACULA THICKNESS; RETINA MACULA VOLUME; SUBRETINAL NEOVASCULARIZATION; VISUAL SYSTEM PARAMETERS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; CASE-CONTROL STUDIES; CATARACT; CHOROID; CHOROIDAL NEOVASCULARIZATION; CYTOKINES; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859021749     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal neovascularization. Optom Vis Sci 2006; 83:316-25. [PMID: 16699445]
2. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104:7-21. [PMID: 9022098]
3. Voykov B, Ziemssen F. Myopic CNV. Klin Monbl Augenheilkd 2011; 228:762-70. [PMID: 21913145]
4. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46:1473-80. [PMID: 9287049]
5. Wolf S, Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Prünte C, Schmidt-Erfurth U, Weichselberger A, Hashad Y. Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. Br J Ophthalmol 2011; 95:1713-8. [PMID: 21951567]
6. Chang TS, Bressler NM, Fine JT. Improved vision-related function after ranibizumab treatment of neovascular agerelated macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007; 125:1460-9. [PMID: 17998507]
7. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008; 12:iii-iv. [PMID:18462575]
8. Koh A, Lim TH, Au Eong KG. Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy. Singapore Med J 2011; 52:232-40. [PMID: 21552782]
9. Ouhadj O, Bouarfa A, Akel S. Intravitreal ranibizumab injections for the treatment of choroidal neovascularization complicating high myopia. J Fr Ophtalmol 2010; 33:649-54. [PMID: 21047702]
10. Heimes B, Lommatzsch A, Zeimer M. Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success. Ophthalmologe 2011; 108:124-31. [PMID: 20535478]
11. Tao Y, Jonas JB. Intravitreal triamcinolone. Ophthalmologica 2011; 225:1-20. [PMID: 20693817]
12. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121:57-61. [PMID: 12523885]
13. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111:218-24. [PMID:15019365]
14. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007; 125:1221-4. [PMID: 17846362]
15. Hageman GS, Luthert PJ, Chong VNH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20:705-32. [PMID: 11587915]
16. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age-related macular degeneration. Exp Eye Res 2001; 73:887-96. [PMID: 11846519]
17. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134:411-31. [PMID: 12208254]
18. Dastgheib K, Green W. Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch Ophthalmol 1994; 112:813-8. [PMID: 7516148]
19. Penfold PL, Killingsworth M, Sarks S. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol 1985; 223:69-76. [PMID:2408968]
20. Killingsworth MC, Sarks J, Sarks S. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye (Lond) 1990; 4:613-21. [PMID: 2226993]
21. Jones LL, Vignali DA. Molecular interactions within the IL-6/ IL-12 cytokine/receptor superfamily. Immunol Res 2011; 51:5-14. [PMID: 21553332]
22. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012; 52:199-219. [PMID: 21910626]
23. Shen Y, Wang D, Wang X. Role of CCR2 and IL-8 in acute lung injury: a new mechanism and therapeutic target. Expert Rev Respir Med 2011; 5:107-14. [PMID: 21348591]
24. Szarka A, Rigo J Jr, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010; 11:59. [PMID:21126355]
25. Krause ML, Davis JM 3rd, Knutson KL. Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis. Clin Immunol 2011; 141:67-72. [PMID: 21703930]
26. Green WR, Key S. Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc 1977; 75:180-254. [PMID: 613523]
27. Grindle CFJ, Marshall J. Ageing changes in Bruch's membrane and their functionalimplications. Trans Ophthalmol Soc U K 1978; 98:172-5. [PMID: 285503]
28. Higgins GT, Wang JH, Dockery P. Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments. Invest Ophthalmol Vis Sci 2003; 44:1775-82. [PMID: 12657621]
29. Goverdhan SV, Ennis S, Hannan SR. Interleukin 8 promoter polymorphism-251A/T is a risk factor for age related macular degeneration. Br J Ophthalmol 2008; 92:537-40. [PMID: 18310311]
30. Izumi-Nagai K, Nagai N, Ozawa Y. Interleukin-6 receptormediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol 2007; 170:2149-58. [PMID:17525280]
31. Ehlken C, Rennel ES, Michels D, Grundel B, Pielen A, Junker B, Stahl A, Hansen LL, Feltgen N, Agostini HT, Martin G. Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion. Am J Ophthalmol 2011; 152:298-303. [PMID: 21621189]
32. Yan H, Cui J, Yu JG. The expression of vascular endothelial growth factor of vitreous in patients with proliferative diabetic retinopathy. Zhonghua Yan Ke Za Zhi 2009; 45:206-9. [PMID: 19575912]
33. Asato R, Kita T, Kawahara S. Vitreous levels of soluble vascular endothelial growth factor receptor (VEGFR)-1 in eyes with vitreoretinal diseases. Br J Ophthalmol 2011; 95:1745-8. [PMID: 21719570]
34. Kawashima M, Shoji J, Nakajima M. Soluble IL-6 receptor in vitreous fluid of patients with proliferative diabetic retinopathy. Jpn J Ophthalmol 2007; 51:100-4. [PMID:17401618]
35. Roh MI, Kim HS, Song JH. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with AMD after bevacizumab treatment. Retina 2009; 29:523-9. [PMID: 19262441]